NASDAQ · Biotechnology

Biodexa Pharmaceuticals Plc (BDRX) Stock

$1.71 -3.39% NASDAQ: BDRX Healthcare

Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023.

Valuation

MetricValue
Price$1.71
Market Cap$1.28M
P/E Ratio0.00
P/B Ratio0.01
P/S Ratio0.00
EPS (TTM)$-400.00
52-Week High$59.40
52-Week Low$1.65
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-55.81%
ROA-35.09%
ROCE-72.66%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio2.03

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$1.0M$0$0$0
Operating Profit$-7.0M$-9.0M$-8.0M$-9.0M$-8.0M
Net Profit$-5.0M$-8.0M$-7.0M$-6.0M$-6.0M
EPS$-4661590.00$-4770680.00$-69640.00$-3705.65$-400.00
Op Margin-1210.7%-1277.8%-2103.4%——

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$13.0M$6.0M$11.0M$15.0M$18.0M
Total Liabilities$2.0M$2.0M$6.0M$6.0M$7.0M
Cash$10.0M$3.0M$6.0M$2.0M$9.0M
Borrowings$1.0M$1.0M$0$1.0M$0

Latest News

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading MT Newswires · Jul 22, 2026 European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading MT Newswires · Jul 20, 2026 European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading MT Newswires · Jul 2, 2026 European Equities Traded in the US as American Depositary Receipts Fall Sharply in Wednesday Trading MT Newswires · Jul 1, 2026 Result of Annual General Meeting GlobeNewswire · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-6.0M$-7.0M$-7.0M$-12.0M$-5.0M
Investing Cash Flow$-1.0M$0$-1.0M$-1.0M$-1.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$3.0M$-7.0M$3.0M$-4.0M$7.0M
Free Cash Flow$-6.0M$-7.0M$-7.0M$-13.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.87
FCF Yield-590.77%
Quick Ratio2.03
Interest Coverage-72.31
Return 1Y-96.20%
Return 3Y-99.98%
Return 5Y-100.00%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BIVI $1.52 +6.29% -0.11 $11.46M 0.00%
CANFCan-Fite BioPharma Ltd. $3.30 -2.37% -0.74 $1.78M 0.00%
CNSP $5.40 +0.75% -0.14 $3.10M 0.00%
ESLAEstrella Immunopharma, Inc. $0.78 +0.06% -2.25 $33.59M 0.00%
GLMD $0.62 +3.67% -0.25 $5.13M 0.00%

About Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.

Biodexa Pharmaceuticals Plc is headquartered in GB.

Biodexa Pharmaceuticals Plc (BDRX) stock trades at $1.71 with a market capitalization of $1.28M. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.65 and $59.40, and currently trades 97.1% below its 52-week high.

On profitability, Biodexa Pharmaceuticals Plc generates a return on equity (ROE) of -55.81%, return on capital employed of -72.66%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.biodexapharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides